Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Artif Intell Gastroenterol. Feb 28, 2021; 2(1): 1-9
Published online Feb 28, 2021. doi: 10.35712/aig.v2.i1.1
Artificial intelligence and machine learning could support drug development for hepatitis A virus internal ribosomal entry sites
Tatsuo Kanda, Reina Sasaki, Ryota Masuzaki, Mitsuhiko Moriyama
Tatsuo Kanda, Reina Sasaki, Ryota Masuzaki, Mitsuhiko Moriyama, Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Itabashi-ku 173-8610, Tokyo, Japan
Author contributions: Kanda T performed the majority of the writing and prepared the figures and tables; Sasaki R performed data acquisition and writing; Masuzaki R provided input in writing the paper; Moriyama M designed the outline and coordinated the writing of the paper; all authors have read and approve the final manuscript.
Supported by The Japan Agency for Medical Research and Development, No. JP20fk0210075.
Conflict-of-interest statement: There is no conflict of interest associated with any authors who contributed their efforts to this manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Tatsuo Kanda, MD, PhD, Associate Professor, Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi-kamicho, Itabashi-ku 173-8610, Tokyo, Japan.
Received: October 15, 2020
Peer-review started: October 15, 2020
First decision: December 17, 2020
Revised: December 29, 2020
Accepted: February 12, 2021
Article in press: February 12, 2021
Published online: February 28, 2021
Core Tip

Core Tip: In certain areas, it is difficult to perform universal hepatitis A virus (HAV) vaccination. We found that several drugs potentially inhibit HAV internal ribosomal entry sites-dependent translation and HAV replication. After the application of machine and deep learning, artificial intelligence identified effective anti-HAV drugs more quickly, using drug repositioning and drug rescue.